Structural mechanisms for VMAT2 inhibition by tetrabenazine

被引：0
作者：
Dalton, Michael P. [1 ]
Cheng, Mary H. [2 ,3 ]
Bahar, Ivet [2 ,3 ]
Coleman, Jonathan [1 ]
机构：
[1] Univ Pittsburgh, Dept Biol Struct, Pittsburgh, PA USA
[2] SUNY Stony Brook, Laufer Ctr Phys & Quantitat Biol, Stony Brook, NY USA
[3] SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY USA
来源：
BIOPHYSICAL JOURNAL | 2024年 / 123卷 / 03期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
625-Pos
引用
收藏
页码：116A / 116A
页数：1
相关论文
共 50 条
  • [21] VMAT2 Inhibition: A Novel Mechanism for Maintained Efficacy at Lowered Antipsychotic Doses
    Grigoriadis, Dimitri
    Hoare, Sam
    Kudwa, Andrea
    Boikess, Steve
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S269 - S270
  • [22] VMAT2 Inhibitors in Neuropsychiatric Disorders
    Arjun Tarakad
    Joohi Jimenez-Shahed
    CNS Drugs, 2018, 32 : 1131 - 1144
  • [23] VMAT2 Inhibitors in Neuropsychiatric Disorders
    Tarakad, Arjun
    Jimenez-Shahed, Joohi
    CNS DRUGS, 2018, 32 (12) : 1131 - 1144
  • [24] Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants
    Wang, Xunan
    Marmouzi, Ilias
    Finnie, Peter S. B.
    Bucher, Meghan L.
    Yan, Yuanye
    Williams, Erin Q.
    Stove, Svein I.
    Lipina, Tatiana V.
    Ramsey, Amy J.
    Miller, Gary W.
    Salahpour, Ali
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 (11) : 1783 - 1791
  • [25] Development of fluorescent substrates for vesicular monoamine transporter 2 (VMAT2) and their application in high throughput screening of VMAT2 inhibitors
    Hu, Gang
    Sames, Dalibor
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [26] VMAT2 inhibitors for the treatment of tardive dyskinesia
    Scorr, Laura M.
    Factor, Stewart A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 389 : 43 - 47
  • [27] VMAT2 Inhibitors for the Treatment of Tardive Dyskinesia
    Warren, Barbara
    Vanderhoef, Dawn
    Johnson, Jessica
    ISSUES IN MENTAL HEALTH NURSING, 2022, 43 (01) : 22 - 31
  • [28] Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
    Terry-Lorenzo, Ryan
    Albrecht, Daniel
    Crouch, Sabrinia
    Wong, Richard
    Loewen, Gordon
    Giri, Nagdeep
    Skor, Heather
    Lin, Kelly
    Sandiego, Christine M.
    Pajonas, Meghan
    Rabiner, Eugenii A.
    Gunn, Roger N.
    Russell, David S.
    Haubenberger, Dietrich
    NEUROPSYCHOPHARMACOLOGY, 2025, : 1093 - 1101
  • [29] Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport
    Thiriot, DS
    Ruoho, AE
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27304 - 27315
  • [30] Motility phenotype in a zebrafish vmat2 mutant
    Sveinsdottir, Hildur Soley
    Decker, Amanda
    Christensen, Christian
    Lucena, Pablo Botella
    Porsteinsson, Haraldur
    Richert, Elena
    Maier, Valerie Helene
    Cornell, Robert
    Karlsson, Karl Aegir
    PLOS ONE, 2022, 17 (01):
12345